Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

Completed

• Conditions: Early Release of Chromogranin A (CgA)
• Interventions: Diagnostic Test: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

• Registration Number: NCT06183047
• Lead Sponsor: Military Institute od Medicine National Research Institute

Brief Summary

The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-01
• Primary Completion: 2023-09-30
• Study Completion: 2023-09-30
• Status Verified: 2023-12
• Study First Submitted: 2023-12-13
• Study First Submitted QC: 2023-12-13
• Last Update Submitted: 2023-12-13
• Study First Posted: 2023-12-27
• Last Update Posted: 2023-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• confirmed NET
• peptide receptor radionuclide therapy (PRRT)

Exclusion Criteria

• lack of patient consent to a clinical trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with neuroendocrine tumours	early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).	We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Primary Outcome Measures

Name	Time	Method
The CgA level change	2016-2023	We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).